Peer-Reviewed Publication
JCO Precis Oncol2026;10(8):e2600373.August 1, 2026Journal Article
Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.
Emily M Russell1, Sarah M Nielsen1, Rachel E Ellsworth2, Heidi Chwan Ko3, Rebecca A Previs3,4, Daniel E Pineda-Alvarez2, Edward D Esplin2, Kevin Hughes5, Stacy W Gray6, Nadine M Tung7, Allison W Kurian8
1Labcorp, San Francisco, CA.
2Invitae Corporation, San Francisco, CA.
3Labcorp, Durham, NC.
4Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, NC.
5Division of Oncologic & Endocrine Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC.
6City of Hope National Medical Center, Duarte, CA.
7Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
8Departments of Medicine and of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, CA.
Abstract
PURPOSE: Recommendations for clinical management of women with germline pathogenic variants (PVs) in breast cancer susceptibility genes vary by gene. The goal of this study was to examine the utilization of risk-reducing strategies and treatments in women with germline PVs in breast cancer susceptibility genes.
METHODS: This cross-sectional study identified women with a PV in at least one of 13 b…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans